3.97
2.93%
-0.12
After Hours:
3.97
Harvard Bioscience Inc. stock is currently priced at $3.97, with a 24-hour trading volume of 122.17K.
It has seen a -2.93% decreased in the last 24 hours and a -4.34% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.19 pivot point. If it approaches the $3.88 support level, significant changes may occur.
Harvard Bioscience Inc. Stock (HBIO) Financials Data
Harvard Bioscience Inc. (HBIO) Revenue 2024
HBIO reported a revenue (TTM) of $112.25 million for the quarter ending December 31, 2023, a -0.96% decline year-over-year.
Harvard Bioscience Inc. (HBIO) Net Income 2024
HBIO net income (TTM) was -$3.42 million for the quarter ending December 31, 2023, a +64.11% increase year-over-year.
Harvard Bioscience Inc. (HBIO) Cash Flow 2024
HBIO recorded a free cash flow (TTM) of $11.72 million for the quarter ending December 31, 2023, a +2,775% increase year-over-year.
Harvard Bioscience Inc. (HBIO) Earnings per Share 2024
HBIO earnings per share (TTM) was -$0.08 for the quarter ending December 31, 2023, a +65.22% growth year-over-year.
Harvard Bioscience Inc. Stock (HBIO) Latest News
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
GlobeNewswire Inc.
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET
GlobeNewswire Inc.
Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023
GlobeNewswire Inc.
Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023
GlobeNewswire Inc.
Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023
GlobeNewswire Inc.
About Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Cap:
|
Volume (24h):